CTC
AST.WS

Central Trust Company’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Central Trust Company’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8
Closed – – 1261
2016
Q4 		$0 Hold
8
– – ﹤0.01% 1245
2016
Q3 		$0 Hold
8
– – ﹤0.01% 1240
2016
Q2 		$0 Buy
+8
New +$4 ﹤0.01% 1210

Other funds holding AST.WS

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Central Trust Company's AST.WS Position: Q1 2017 in Review

Central Trust Company sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q1 2017, closing a stake of 8 shares.

Central Trust Company first reported a position in AST.WS in Q2 2016 and held it in 3 quarters. The position peaked at $0 in Q4 2016. 35 funds tracked by Wall St. Rank hold AST.WS as of Q1 2017.

  • Central Trust Company reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q1 2017 after selling out during the quarter.
  • Central Trust Company sold 8 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q1 2017.
  • Central Trust Company first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 3 quarters.
  • Central Trust Company's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $0 in Q4 2016.
  • 35 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q1 2017.

Based on Central Trust Company's 13F filing for Q1 2017, filed 6 Apr 2017.